EndocannabinoidSystem内源性大麻素system.pptVIP

Targeting the endocannabinoid system: to enhance or reduce?;Introduction Ups and downs of endocannabinoids in disease Therapeutic use of indirect agonists Therapeutic use of inverse agonists/antagonists;;;Recptors;;Development strategy of endocannabinoid system targeted drug;Introduction Ups and downs of endocannabinoids in disease Therapeutic use of indirect agonists Therapeutic use of inverse agonists/antagonists;NOTE;Eatting disorders;Neural-disease;;Roles of endocannabinoids duringcentral neuroinflammation;Roles of endocannabinoids duringperipheral neuroinflammation;Liver disease and osteoporosis;Other diseases;Introduction Ups and downs of endocannabinoids in disease Therapeutic use of indirect agonists Therapeutic use of inverse agonists/antagonists;Inhibitors of catabolism;Endocannabinoid indirect agonists: inhibitors of FAAH and MAGL;Inhibitors of cellular reuptake;Endocannabinoid indirect agonists: Inhibitors of cellular reuptake;Potential disadvantages;Introduction Ups and downs of endocannabinoids in disease Therapeutic use of indirect agonists Therapeutic use of inverse agonists/antagonists;;CB1 receptor antagonists/inverse agonists in clinical trials (not all);CB2 receptor antagonists/inverse agonists in preclinical trials (not all);Potential disadvantages;Perhaps no other signalling system discovered during the past 15 years is raising as many expectations for the development of new therapeutic drugs, encompassing such a variety of pathological conditions, targeting so many different organs and tissues, and using such a wide range of potential strategies for treatment, as the endocannabinoid system.